FDA Fast Track Accelerates Gamgertamig for Refractory AIHA FDA Fast Track designation highlights gamgertamig’s potential to address unmet needs in cold and warm AIHA, as well as ITP.

The @fda.gov has granted #FastTrack designation to #Gamgertamig (#OM336) for the treatment of cold and warm autoimmune hemolytic anemia (#AIHA) and immune thrombocytopenia (#ITP),

Read here: https://bit.ly/4bz3UeT

#RareDisease #MedSky

Ouro Medicines Achieves FDA Fast Track Designation for Gamgertamig in Treating Serious Autoimmune Diseases Ouro Medicines has received U.S. FDA Fast Track designation for Gamgertamig, aimed at treating life-threatening autoimmune disorders like ITP and AIHA.

Ouro Medicines Achieves FDA Fast Track Designation for Gamgertamig in Treating Serious Autoimmune Diseases #United_States #FDA #South_San_Francisco #Ouro_Medicines #Gamgertamig

Ouro Medicines Achieves FDA Orphan Drug Designation for Gamgertamig in Treating Immune Thrombocytopenia Ouro Medicines secures FDA Orphan Drug Designation for Gamgertamig, aimed at treating immune thrombocytopenia. This marks a significant milestone in its development process.

Ouro Medicines Achieves FDA Orphan Drug Designation for Gamgertamig in Treating Immune Thrombocytopenia #United_States #South_San_Francisco #Ouro_Medicines #FDA_Orphan_Drug #Gamgertamig